Apogee Therapeutics, Inc. (APGE) Current Ratio
- Current ratio · latest quarter: Value 26.44×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 26.44× | Current assets / current liabilities. $991.73M ÷ $37.51M ≈ 26.44× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 991.73M USD | Assets, Current |
| Current obligations | 37.51M USD | Liabilities, Current |
| Cash and equivalents | 105.57M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 866.36M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.08M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $991.73M | $37.51M | $105.57M | $866.36M | (m) | (m) | $3.08M | (m) | 26.44× |
| 2026-03-31 | $1.07B | $32.95M | $451.80M | $608.09M | (m) | (m) | $1.24M | (m) | 32.59× |
| 2025-12-31 | $741.36M | $27.91M | (m) | $598.64M | (m) | (m) | $1.22M | (m) | 26.57× |
| 2025-09-30 | $540.10M | $34.05M | $107.91M | $419.38M | (m) | (m) | $376.00K | (m) | 15.86× |
| 2025-06-30 | $516.12M | $31.55M | $124.19M | $381.23M | (m) | (m) | $5.68M | (m) | 16.36× |
| 2025-03-31 | $521.53M | $32.96M | $106.92M | $406.41M | (m) | (m) | $2.44M | (m) | 15.82× |
| 2024-12-31 | $529.71M | $28.56M | $141.79M | $378.86M | (m) | (m) | $1.07M | (m) | 18.55× |
| 2024-09-30 | $534.48M | $32.61M | $118.78M | $407.27M | (m) | (m) | $2.22M | (m) | 16.39× |
| 2024-06-30 | $681.85M | $24.62M | $307.30M | $368.93M | (m) | (m) | $5.53M | (m) | 27.70× |
| 2024-03-31 | $820.61M | $21.55M | $485.46M | $330.74M | (m) | (m) | $4.30M | (m) | 38.08× |
| 2023-12-31 | $398.41M | $20.56M | $118.32M | $277.14M | (m) | (m) | $2.14M | (m) | 19.38× |
| 2023-09-30 | $426.42M | $17.18M | (m) | $234.59M | (m) | (m) | $1.21M | (m) | 24.82× |
| 2023-06-30 | $130.67M | $17.61M | (m) | (m) | (m) | (m) | $11.15M | (m) | 7.42× |
| 2022-12-31 | $152.06M | $9.98M | $151.89M | (m) | (m) | (m) | $418.00K | (m) | 15.24× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.